NEUROENDOCRINE TUMOR G2
Clinical trials for NEUROENDOCRINE TUMOR G2 explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE TUMOR G2 trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE TUMOR G2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for neuroendocrine tumors: cabozantinib shows promise in Late-Stage trial
Disease control OngoingThis phase 3 study tests the drug cabozantinib against a placebo in 298 people with advanced neuroendocrine tumors (including carcinoid tumors) that have worsened after prior treatment. Cabozantinib is a targeted therapy that may slow or stop tumor growth by blocking certain prot…
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Major trial tests two drug cocktails for rare gut cancers
Disease control OngoingThis study compares two drug combinations for people with advanced neuroendocrine tumors (a type of slow-growing cancer). 427 participants received either octreotide plus interferon or octreotide plus bevacizumab. The goal is to see which combination better delays cancer growth. …
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New drug shows promise in slowing carcinoid tumors
Disease control OngoingThis study tests a drug called pazopanib in 171 people with carcinoid tumors that are getting worse. The goal is to see if pazopanib can slow or stop tumor growth compared to a placebo. Participants take the drug daily and are monitored for how long their disease stays stable.
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC